Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article reviews adverse drug reactions, emphasizes methods of prevention, and encourages reporting to the FDA's medWatch program, but presents no new study findings.

This study reviewed therapies for alopecia areata and suggests that Janus kinase inhibitors, such as baricitinib and upadacitinib, show promise in treating both alopecia areata and associated immune-mediated inflammatory diseases.

In this real-world study, 27% of alopecia areata patients treated with ritlecitinib achieved a target SALT score, a result consistent with clinical trial findings, highlighting the value of patient-reported outcomes in understanding treatment impact beyond traditional measures.

This study found that two novel nonsteroidal derivatives inhibited specific enzymes in vitro and in vivo, leading to dihydrotestosterone accumulation in androgen-dependent glands, suggesting potential therapeutic use for mood improvement in the elderly.

In this case study, a neoadjuvant therapy combining gemcitabine and Disitamab Vedotin proved effective and safe for a muscle-invasive bladder cancer patient with severe renal insufficiency, who could not tolerate platinum-based treatments. The study suggests this regimen may be a viable alternative, pending further research.

This phase Ib study found that combining pegylated liposomal doxorubicin and pembrolizumab was well-tolerated and effective, with durable antitumor responses and a median survival of over two years in heavily pretreated ER-positive metastatic breast cancer patients.

This case report discusses rare but serious cardiac complications, including pericarditis and edema, observed with low-dose oral minoxidil for hair loss, highlighting the need for cautious prescribing, especially in high-risk patients.

This study found that apremilast treatment did not result in sustained improvement for most patients with treatment-resistant alopecia areata, although one patient experienced significant benefit.

This study describes the positive effects of the JAK inhibitor ruxolitinib in treating autoimmune manifestations in three patients with autoimmune polyendocrine syndrome type-1 over a period of at least 30 months, with excellent tolerance and no adverse events observed.

This study conducted a large-scale comparison using FAERS data to assess the post-marketing safety profiles of spironolactone, eplerenone, and finerenone, finding unique adverse event patterns for each drug and highlighting the need for personalized safety monitoring and further investigation in other pharmacovigilance databases.

In this case report, upadacitinib was used to treat a 21-year-old female with severe alopecia areata, resulting in significant hair regrowth; however, rapid hair loss recurred soon after discontinuing the drug, illustrating its potential efficacy as well as the risk of relapse upon stopping treatment.

This case report describes a patient with permanent chemotherapy-induced alopecia who experienced full hair regrowth after treatment with low-dose oral minoxidil.

This case study highlights the importance of early detection and management of pembrolizumab-induced hepatitis, suggesting that early steroid treatment could potentially prevent severe complications.

This study reported that in a case series of three adolescents with alopecia areata and atopic dermatitis, treatment with 15 mg/day of upadacitinib led to rapid improvement in skin symptoms and significant hair regrowth over 12 months, with no severe adverse events observed.

This article reviews potential causes for angiolymphoid hyperplasia with eosinophilia, a benign vascular tumor often found in middle-aged adults, and reports no new clinical findings.

This study reviewed adverse events associated with low-dose oral minoxidil for treating alopecia, finding hypertrichosis and fluid retention as common, typically manageable side effects without needing treatment discontinuation.

This study describes and characterizes four cases of alopecia areata induced by immune checkpoint inhibitor therapy in cancer patients, highlighting the importance of recognizing and managing these hair-related adverse events.

This study evaluated eight JAK inhibitor regimens for alopecia areata and provided high-quality evidence on their comparative effectiveness, which can aid clinicians in decision-making and inform medical practice guidelines.

Ritlecitinib shows promise for treating alopecia areata, especially with early and extended treatment.

In this review, researchers discuss 50 novel drugs approved by the FDA in 2024, highlighting key agents like vadadustat for anemia in chronic kidney disease and donanemab for Alzheimer’s, and focusing on their roles in pharmacy education and clinical decision-making.

This study compared the adverse effects of baricitinib and methotrexate in treating severe alopecia areata and found baricitinib to have a better safety profile, though it was associated with increased cholesterol, triglyceride, and LDL levels.

In this study, behavioral disturbances were commonly observed with levetiracetam, while somnolence was frequently reported with oxcarbazepine among patients with refractory epilepsy.

In this study, low-dose naltrexone significantly reduced erythema in patients with frontal fibrosing alopecia and lichen planopilaris after one year, but no significant improvements were seen in other symptoms.

A cancer patient developed a type of hair loss after starting a cancer drug called vandetanib.

In this study, tofacitinib showed promising efficacy and safety for biologic-naïve elderly patients with moderate-to-severe ulcerative colitis, achieving steroid-free remission and clinical response over 52 weeks.

This study observed that upadacitinib demonstrated significant efficacy and favorable safety for treating alopecia areata over 12 months in a real-world setting, with patients having an atopic background showing better early response; no serious adverse events were reported.

This study found that adding concurrent and adjuvant temozolomide to radiotherapy for patients with anaplastic gliomas improved progression-free survival without adversely affecting health-related quality of life.

This review by Aceituno et al. found that both baricitinib and ritlecitinib demonstrate strong efficacy for severe alopecia areata, with meaningful hair regrowth by Week 24, but notes limitations like differing trial sizes and potential effect size overestimations.